Periosteum-covered ACI (ACI-P) versus collagen membrane ACI (ACI-C): A single-surgeon, large cohort analysis of clinical outcomes and graft survivorship
Liana Leja, MS, Tom Minas, MD, MS
Journal of Cartilage & Joint Preservation · 2021
doi:10.1016/j.jcjp.2021.100010 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Introduction: Autologous chondrocyte implantation (ACI) has undergone several technical modifications. Objectives: To compare clinical outcomes and graft survivorship between ''first-generation'' periosteum-covered ACI (ACI-P) and ''second-generation'' collagen membrane ACI (ACI-C). Methods: A total of 400 consecutive ACI cases performed by a single surgeon were reviewed. Of the total, 200 were treated with ACI-P and 200 ACI-C. Patients with a minimum follow-up of 2 years were included (ACI-P, n = 112; ACI-C, n = 94). A separate long-term analysis was completed with a mean follow-up of 9 ± 1.8 years in the ACI-P group and 12 ± 2.2 years in the ACI-C group. Clinical outcomes and graft survivorship were compared at both follow-up intervals. Predictors of treatment failures and subsequent surgical procedures (SSPs) were identified. Results: Treatment failures were significantly greater among ACI-P cases compared to ACI-C, P =.007 with a greater proportion of cases with disease progression in the ACI-P cohort, P =.022. SSPs were greater in the ACI-P cohort, P <.001. Debridement for symptomatic hypertrophy was the most frequently performed SSP among ACI-P cases. ACI generation and prior marrow stimulation were significant predictors of treatment failures and SSPs. There were significant mean improvements in patient subjective responses within treatment groups. No differences in patient subjective responses were observed between ACI generations. Cumulative graft survivorship was greater in the ACI-C cohort (P =.024). Conclusions: The use of ACI-C improved clinical outcomes with a reduction in treatment failures, SSPs, and graft hypertrophy, allowing the surgeon to treat a greater number of bipolar and multiple lesion cases with similar functional outcomes when compared to ACI-P.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.